Clinical—LiverAmino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir

Add time:08/19/2019    Source:sciencedirect.com

Background & AimsSofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C virus (HCV) polymerase. This drug eliminates most chronic HCV infections, and resistance-associated substitutions in the polymerase are rare. However, HCV genotype 3 responds slightly less well to sofosbuvir-based therapies than other genotypes. We collected data from England’s National Health Service Early Access Program to search for virus factors associated with sofosbuvir treatment failure.

We also recommend Trading Suppliers and Manufacturers of (3A S-CIS)-(-)-3,3A,8,8A-TETRAHYDRO-2H-INDENO[1,2-D]OXAZOL-2-ONE (cas 135969-64-1). Pls Click Website Link as below: cas 135969-64-1 suppliers

Prev:Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and LENOGRASTIM (cas 135968-09-1) (Granocyte®) in CD34+ peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors
Next:Research paperC1-symmetrical cis-bis(di-2-pyridylamine)chloro(dimethyl sulfoxide-S)ruthenium(II) complex: Synthesis, crystal structure, and anion recognition using the NH groups in the chelating ligands)